Published in:
Open Access
01-12-2015 | Research article
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
Authors:
Hua Gao, Fei Wang, Xiaolei Lan, Chuzhong Li, Jie Feng, Jiwei Bai, Lei Cao, Songbai Gui, Lichuan Hong, Yazhuo Zhang
Published in:
BMC Cancer
|
Issue 1/2015
Login to get access
Abstract
Background
Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25–30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5–18% of patients.
Methods
The exomes of six responsive prolactinomas and six resistant prolactinomas were analyzed by whole-exome sequencing.
Results
Using stringent variant calling and filtering parameters, ten somatic variants that were mainly associated with DNA repair or protein metabolic processes were identified. New resistant variants were identified in multiple genes including PRDM2, PRG4, MUC4, DSPP, DPCR1, RP1L1, MX2, POTEF, C1orf170, and KRTAP10-3. The expression of these genes was then quantified by real-time reverse-transcription PCR (RT–qPCR) in 12 prolactinomas and 3 normal pituitary glands. The mRNA levels of PRDM2 were approximately five-fold lower in resistant prolactinomas than in responsive tumors (p < 0.05). PRDM2 protein levels were lower in resistant prolactinomas than in responsive tumors, as determined by Western blotting and immunohistochemical analysis (p < 0.05). Overexpression of PRDM2 upregulated dopamine receptor D2 (D2DR) and inhibited the phosphorylation of ERK1/2 in MMQ cells. PRDM2 showed a synergistic effect with BRC on the inhibition of prolactin (PRL) secretion and MMQ cell viability, and low PRDM2 expression was associated with tumor recurrence.
Conclusions
PRDM2 downregulation may play a role in dopamine-agonist resistance and tumor recurrence in prolactinomas.